Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

NHS semaglutide spending in London has surged from £242K in 2019 to £15.6m in 2024. Find out what's driving demand and the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...